Lung Cancer: Targets and Therapy, Volume 13, Issue (2022)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Lung Cancer: Targets and Therapy, Volume 13, Issue (2022)

See all volumes and issues
Vol 15, 2024 Vol 14, 2023 Volume 13, 2022 Vol 12, 2021 Vol 11, 2020 Vol 10, 2019 Vol 9, 2018 Vol 8, 2017 Vol 7, 2016 Vol 6, 2015 Vol 5, 2014 Vol 4, 2013 Vol 3, 2012 Vol 2, 2011 Vol 1, 2010
Download citations Download PDFs Download issue

Review

Review Article
An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
Alexander Davis, Helen Ke, Steven Kao & Nick Pavlakis
Pages: 1-12
Published online: 02 Mar 2022
AbstractforAn Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma | Full Text | References | PDF (508.9 KB) | EPUB
  • 380 Views
  • 3 CrossRef citations
  • 0Altmetric
Open Access

Commentary

Article Commentary
ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
Misako Nagasaka & Sai-hong Ignatius Ou
Pages: 13-21
Published online: 16 Nov 2022
AbstractforORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression? | Full Text | References | PDF (2.1 MB) | EPUB
  • 189 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Article Commentary
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
Shannon S Zhang & Sai-Hong Ignatius Ou
Pages: 23-31
Published online: 26 Apr 2022
AbstractforDeconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib | Full Text | References | PDF (815.4 KB) | EPUB
  • 147 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Perspectives

Discussion
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Danielle Brazel, Shannon Zhang & Misako Nagasaka
Pages: 33-45
Published online: 16 Nov 2022
AbstractforSpotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation | Full Text | References | PDF (454.1 KB) | EPUB
  • 453 Views
  • 2 CrossRef citations
  • 0Altmetric
Open Access

Review

Review Article
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
Danielle Brazel & Misako Nagasaka
Pages: 47-52
Published online: 19 May 2022
AbstractforDeconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC | Full Text | References | PDF (330.2 KB) | EPUB
  • 133 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

REVIEW

Review
Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
Joséphine Carpentier, Iuliia Pavlyk, Uma Mukherjee, Peter E Hall & Peter W Szlosarek
Pages: 53-66
Published online: 05 Sep 2022
AbstractforArginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy | Full Text | References | PDF (2.8 MB) | EPUB
  • 240 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Review
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Danielle Brazel, Zhaohui Arter & Misako Nagasaka
Pages: 75-80
Published online: 29 Nov 2022
AbstractforA Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib | Full Text | References | PDF (373.2 KB) | EPUB
  • 220 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Review
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
Shannon S Zhang & Sai-hong Ignatius Ou
Pages: 67-73
Published online: 23 Dec 2022
AbstractforSpotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs? | Full Text | References | PDF (1.1 MB) | EPUB
  • 306 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Explore articles